# Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)

> **NCT07209189** · PHASE2 · RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 75 (estimated)

## Conditions studied

- Head and Neck Cancer
- Squamous Cell Carcinoma
- Oral Cavity Cancer
- Oropharyngeal Cancer
- Laryngeal Cancer
- Sinonasal Squamous Cell Carcinoma
- HPV (Human Papillomavirus)-Associated Carcinoma
- Skull Base Tumors
- HPV 16 Positive Oropharyngeal Tumors (OPC)

## Interventions

- **DRUG:** Toripalimab + Chemotherapy
- **DRUG:** Toripalimab
- **RADIATION:** Chemoradiotherapy or radiation

## Key facts

- **NCT ID:** NCT07209189
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-18
- **Primary completion:** 2030-10-01
- **Final completion:** 2030-12-01
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07209189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07209189, "Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07209189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*